Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB-409513
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
SB-409513 is a small molecule investigational compound classified as an aminobenzoic acid derivative. It acts as an inhibitor of glycogen synthase kinase‑3 beta (GSK‑3β), a serine/threonine protein kinase involved in numerous cellular processes including metabolism and cell signaling. The drug has been studied primarily as a research tool and discovery agent rather than for clinical use. There are no approved indications or advanced clinical trials reported for this compound[1][4][3].
- Other names
- 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid2-Chloro-5-[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yamino]-benzoic acid
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on SB-409513.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB-409513.